2 Possible COVID-19 Vaccines Given Fast-Track Status
Biopharmaceutical New Technologies (BioNTech) for the investigational vaccines BNT162b1 and BNT162b1. The vaccines are the result of a joint research venture between Pfizer and Biopharmaceutical New Technologies (BioNTech).
The search for a vaccine to for coronavirus disease 2019 (COVID-19) got a push from the US Food and Drug Administration (FDA) yesterday when the agency granted fast track status for 2 products under development. The agency gave the go-ahead to Pfizer and Biopharmaceutical New Technologies (BioNTech) for the investigational vaccines BNT162b1 and BNT162b1. The vaccines are the result of a joint research venture between the biopharmaceutical companies.
BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in the 2 companies’ BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the US and Germany.
“The FDA’s decision to grant these two COVID-19 vaccine candidates Fast Track designation signifies an important milestone in the efforts to develop a safe and effective vaccine against SARS-CoV-2,” Peter Honig, senior vice president, Global Regulatory Affairs, Pfizer, said. “We look forward to continue working closely with the FDA throughout the clinical development of this program, Project Lightspeed, to evaluate the safety and efficacy of these vaccine candidates.”
Project Lightspeed is a vaccine development program, which is based on BioNTech’s proprietary mRNA-based technology platforms and supported by Pfizer’s global vaccine development capabilities. The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world.
“We are pleased to have received Fast Track designation from the FDA for two of our vaccine candidates and look forward to working closely with the FDA, along with our partner Pfizer, to expedite the clinical development path forward,” Chief Medical Officer Özlem Türeci at BioNTech reiterated.
Pfizer and BioNTech are developing these novel vaccines with pre-clinical and clinical data at the forefront of all decision-making of both companies.
Along with the development and manufacture of health care products, including medicines, Pfizer has a well-established footprint in vaccines.
BioNTech is an immunotherapy company working on novel therapies for cancer and other serious diseases.
The companies are expecting to start a Phase 2b/3 trial possibly later this month and are anticipating enrolling up to 30,000 subjects.
According to the companies’ joint release, if the ongoing studies are successful, and the vaccine candidate receives regulatory approval, the companies currently expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.
This story first appeared in ContagionLive!®
Healing With Algorithms: AI's Impact on Epidemiology and Infection Control
April 2nd 2024Media in the US presents AI as both beneficial and risky. Positive coverage shows AI's potential through virtual assistants like Siri, while cautionary tales warn of misuse like misinformation and deepfakes. How does all this work in health care?
Four Years After COVID-19: What Has the Infection Prevention Community Learned?
March 15th 2024Four years ago today, March 15, 2020, the COVID-19 lockdown began, and since then, the world has undergone significant changes. It has been a terrifying experience for everyone, especially for the infection prevention community, both within and outside of the health care sector. However, a crucial question remains unanswered: What has the infection prevention community learned from this pandemic, and where does it go from here?
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
